Several randomized trials have demonstrated improved survival rates and local control when concurrent cisplatin-based chemotherapy was added to radiation therapy in patients with locoregionally advanced cervical cancer. Randomized trials that investigated the administration of neoadjuvant chemotherapy before radiation therapy, however, have failed to demonstrate a benefit of this approach. Based on clinical trial evidence cisplatin-based chemoradiation should be considered a standard treatment for most patients with locoregionally advanced carcinoma of the cervix who do not have medical contraindications to this aggressive treatment.
